David Lee, MD, professor of Clinical Urology at UCI Health, discusses how multidisciplinary collaboration and the circumstances of the pandemic led to an increase in the rate of same-day discharge following robotic surgery in patients with prostate cancer. Lee is a robotic surgery expert who has completed more than 6300 robotic surgical procedures.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.